A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.

After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. FDA approved its Bruton’s tyrosine kinase (BTK) inhibitor Calquence ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $207.67 billion and ...

Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients ...

AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

(Alliance News) - AstraZeneca PLC on Friday said its drug Calquence, in combination with chemoimmunotherapy, has received approval from the US Food & Drug Administration for the treatment of adult ...

The FDA has approved Calquence (acalabrutinib) for use in combination with bendamustine and rituximab to treat adults with previously untreated MCL who are ineligible for transplant.